Category: Latest News
-
Apple to adopt Samsung’s crease-free display tech for upcoming foldable iPhone – Analyst Kuo
Apple (NASDAQ:AAPL) is set to utilize Samsung Display’s crease-free screen technology for its foldable iPhone, which is expected to enter large-scale production in the latter half of 2026, according to Ming-Chi Kuo from TF International Securities. Rather than creating its own folding screen design, Apple will rely on Samsung’s proven solution to ensure consistent mass…
-
Encompass Health shares drop after New York Times highlights rehab hospital safety issues
Shares of Encompass Health Corporation (NYSE:EHC) declined 3.6% following a New York Times investigation that raised concerns about patient safety at rehabilitation hospitals, including several serious incidents at Encompass facilities. The report revealed that Encompass Health, a leading provider in the rehab hospital sector, along with other for-profit operators, has faced rare but severe patient…
-
Tesla’s North America Sales Head Steps Down Amid Declining Sales, Reports WSJ
Troy Jones, who led Tesla’s (NASDAQ:TSLA) sales operations across North America, has exited the company after a 15-year tenure, according to sources cited by the Wall Street Journal. Jones held the role of vice president overseeing sales, service, and delivery in Tesla’s biggest market. His departure marks the latest in a series of high-profile executive…
-
Nvidia Shares Surge as H20 Chip Sales Resume in China and New Processor Unveiled
NVIDIA Corporation (NASDAQ:NVDA) announced Monday evening that it will soon resume sales of its H20 processor in China, signaling a positive shift in trade relations between the U.S. and China. This update follows recent meetings between CEO Jensen Huang and officials from both countries. In addition, Nvidia introduced a new graphics processing unit tailored specifically…
-
GE Vernova Stock Reaches Record High of $557.38
Shares of GE Vernova LLC (NYSE:GEV) surged to an all-time peak of $557.38, marking a major milestone for the company, which now boasts a market capitalization of $151 billion. Over the past year, the stock has soared by a remarkable 204.24%, reflecting strong investor confidence fueled by strategic moves and favorable market trends. The company’s…
-
Coupang Stock Climbs to 52-Week High of $30.97
Shares of Coupang LLC (NYSE:CPNG) have hit a 52-week peak at $30.97, pushing the company’s market value to approximately $56 billion. This milestone reflects a strong growth trend for the South Korean e-commerce leader, with the stock rising an impressive 44.49% over the past year. Analyst price targets vary between $22.80 and $37.70, signaling robust…
-
BTC Digital Shares Drop Following $6 Million Share Offering
BTC Digital Ltd. (NASDAQ:BTCT) saw its stock decline by 15% after announcing a registered direct offering of $6 million targeted at institutional investors. The company plans to issue 2 million ordinary shares priced at $3.00 each, according to a statement released today. The funds raised, combined with current cash reserves, will be used to acquire…
-
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network
Citius Oncology, Inc. (NASDAQ:CTOR) saw its stock rise 4.1% after announcing a new distribution services agreement with Cencora to broaden the reach of its FDA-approved immunotherapy, LYMPHIR. The deal with Cencora—formerly AmerisourceBergen (NYSE:COR)—will extend the wholesale distribution of LYMPHIR (denileukin diftitox-cxdl) through Cencora’s extensive specialty distribution network. LYMPHIR gained FDA approval in August 2024 for…
-
Roblox Stock Climbs to 52-Week Peak at $112
Roblox Corporation (NYSE:RBLX) hit a notable milestone, with its stock reaching a 52-week high of $112, valuing the company at approximately $75.2 billion. This surge reflects a remarkable 170.35% increase over the past year, fueled by a solid 30.24% rise in revenue, underscoring strong investor confidence and a promising growth outlook. Recent analyst activity further…
-
Kairos Pharma Shares Surge on Promising Safety Data for Prostate Cancer Treatment
Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic castration-resistant prostate cancer. The interim safety review revealed that ENV-105 (carotuximab), a novel CD105 antagonist, was well tolerated when used alongside the standard hormone therapy, apalutamide.…